STOCK TITAN

BiomX (PHGE) Stock News, Dec 2024-Jul 2025

PHGE NYSE

Ticker history: PHGE became HLSQ (Tessera Defense and Homeland Security Inc.) on .

Historical ticker: BiomX Inc. changed its name to Tessera Defense and Homeland Security Inc. and began trading as HLSQ on September 11, 2026. PHGE news and SEC filings are retained here with their original names and dates. The profile below describes the earlier BiomX business.

BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.

PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.

Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.

BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.

Rhea-AI Summary

BiomX (NYSE American: PHGE) has published Phase 1b/2a Part 1 trial results of its phage cocktail BX004 in Nature Communications, demonstrating significant efficacy against antibiotic-resistant P. aeruginosa infections in cystic fibrosis patients.

The study revealed a remarkable 500-fold (2.7 log₁₀) bacterial reduction compared to placebo, with no emerging resistance. Key findings include a strong safety profile, successful bacterial reduction achieved at day 15, and therapeutic phages reaching and persisting at infection sites. The treatment demonstrated favorable microbiome composition shifts and maintained efficacy where traditional antibiotics often fail.

BiomX is currently advancing its Phase 2b trial of BX004, with topline results expected in Q1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Summary

BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the Biomed Israel 2025 conference in Tel Aviv, Israel, from May 20-22, 2025. The presentation will focus on the company's positive topline Phase 2 results for BX211, a phage therapy targeting Staphylococcus aureus in Diabetic Foot Osteomyelitis (DFO). Solomon will deliver an oral presentation titled "Precision Phage Therapy for Chronic Diabetic Foot Infections" during the Immunology & Inflammation session on May 21, 2025, at the InterContinental David Tel Aviv.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
conferences
-
Rhea-AI Summary

BiomX (NYSE: PHGE) reported significant progress in Q1 2025, highlighted by positive Phase 2 trial results for BX211 in treating diabetic foot osteomyelitis (DFO). The trial demonstrated statistically significant improvements in ulcer size reduction and depth compared to placebo. BX211's development has been supported by $40 million in non-dilutive funding from the U.S. Defense Health Agency.

The company's BX004 Phase 2b study in Cystic Fibrosis remains on track for topline results in Q1 2026. In April 2025, shareholders approved warrant exercises from $12 million in financings announced in February 2025. The company's cash balance stood at $21.2 million as of March 31, 2025, with runway expected through Q1 2026. Q1 2025 financial results showed a net loss of $7.7 million, improved from $17.3 million in Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has scheduled its first quarter 2025 financial results conference call and webcast for Thursday, May 15, 2025, at 2:00 p.m. ET. During the call, the company will discuss Q1 2025 financial performance and provide updates on its business operations and programs. Interested participants can join via phone by dialing 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website at www.biomx.com, where it will also be archived for future viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences earnings date
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on phage therapies, has disclosed that its independent registered public accounting firm included a going concern qualification in their audit opinion for the fiscal year ended December 31, 2024. This disclosure, which was previously included in the Company's annual report on Form 10-K filed on March 25, 2025, is being announced separately to comply with NYSE American Company Guide Sections 401(h) and 610(b). The company emphasizes that this announcement does not represent any changes or amendments to their 2024 audited financial statements or annual report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
none
-
Rhea-AI Summary

BiomX (NYSE: PHGE) announced positive topline results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). The trial demonstrated that BX211 was safe and well-tolerated, producing statistically significant improvements in multiple areas:

  • Sustained reduction in ulcer size (PAR) with p=0.046 at week 12
  • Significant improvements in ulcer depth at week 13 (p=0.048)
  • Reduced expansion of ulcer area (p=0.017)

The study involved 41 patients randomized at a 2:1 ratio, with 26 receiving BX211 and 15 receiving placebo. Treatment showed separation from placebo starting at week 7, with a difference greater than 40% by week 10. The company is now planning for a Phase 2/3 trial, pending FDA feedback.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
Rhea-AI Summary

BiomX (NYSE: PHGE) announced its Q4 and full year 2024 financial results, highlighting key developments in its phage therapy programs. The company secured $12 million in financing in February 2025 to support its Phase 2b study of BX004. Key financial metrics include:

- Cash balance of $18.0 million as of December 31, 2024
- R&D expenses increased to $24.7 million in 2024
- Net loss decreased to $17.7 million in 2024
- Operating cash burn of $37 million in 2024

Clinical Updates:

  • BX211 Phase 2 topline results for diabetic foot osteomyelitis expected by end of March 2025
  • BX004 Phase 2b topline results for cystic fibrosis anticipated in Q1 2026
  • Received $36.8 million in non-dilutive funding from DHA for BX211 trial

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has announced it will release its fourth quarter and full year 2024 financial results on March 25, 2025.

The financial results will be accessible through a press release in the Investors section of BiomX's website. The company plans to host a conference call and audio webcast at a later date, which will coincide with the announcement of initial topline results from its Phase 2 trial investigating treatments for subjects with diabetic foot osteomyelitis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
conferences earnings
-
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE) has secured $12 million in financing through a series of offerings, including a registered direct offering and concurrent private placement. The funding will support the advancement of their BX004 program through Phase 2b study in cystic fibrosis patients, with topline results expected in Q1 2026.

The offerings were led by Deerfield Management Company with significant participation from the Cystic Fibrosis Foundation and Nantahala Capital. The financing includes the purchase of 3,633,514 shares of common stock at $0.9306 per share, along with warrants for additional shares. The company will also analyze real-world evidence exploring the relationship between P. aeruginosa reduction and clinical outcomes in CF patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.03%
Tags
none
Rhea-AI Summary

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none

FAQ

What is the current stock price of BiomX (PHGE)?

BiomX (PHGE) last closed at $1.85. The company now trades as HLSQ.